Subsequently, we examined the relative risk for all-cause mortality of patients with different FLT3/ITD AR, which underwent a fitting curve analysis with the aim of confirming the optimal threshold of FLT3/ITD AR that was observed in such a large sample of FLT3/ITD-positive pediatric AML patients and finally the turning point was selected by using Cox proportional hazards models. The gene discussed is FLT3; the disease is acute myeloid leukemia.